Page last updated: 2024-12-05

n-amylamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

n-amylamine: strong irritant; RN given refers to parent cpd; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

pentan-1-amine : A primary aliphatic amine that is n-pentane in which a hydrogen of one of the methyl groups is replaced by an amino group. A water-soluble liquid with boiling point 104degreeC, it is a strong irritant. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID8060
CHEBI ID74848
MeSH IDM0046678

Synonyms (59)

Synonym
n-amylamine
n-pentylamine
1-aminopentane
110-58-7
1-pentylamine
nsc7906
pentylamine
monoamylamine
nsc-7906
1-pentanamine
amylamine
norleucamine
pentan-1-amine
AML ,
inchi=1/c5h13n/c1-2-3-4-5-6/h2-6h2,1h
brn 0505953
einecs 203-780-2
nsc 7906
ai3-15379
ccris 6210
amylamine, >=99%, fg
DB02045
amylamine, 99%
A0445
AKOS000119067
BBL011398
amyl amine
STL146502
e05qm3v8ef ,
unii-e05qm3v8ef
ec 203-780-2
4-04-00-00674 (beilstein handbook reference)
FT-0622370
CHEBI:74848
me(ch2)4nh2
ch3(ch2)4nh2
n-c5h11nh2
n-amnh2
fema no. 4242
pentylamine [fhfi]
n-amylamine [mi]
pentyl amine
n-pentyl amine
3-ethyl-propylamine
n--amylamine
STR07758
DTXSID0021919
J-519589
J-002450
F2190-0404
amylamine, analytical standard
monopentylamine
mfcd00008236
10.14272/DPBLXKKOBLCELK-UHFFFAOYSA-N.1
doi:10.14272/dpblxkkoblcelk-uhfffaoysa-n.1
Q766883
AMY21878
EN300-19020
Z104472246
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
primary aliphatic amine
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (13)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (30.77)18.7374
1990's2 (15.38)18.2507
2000's3 (23.08)29.6817
2010's4 (30.77)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 19.45

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index19.45 (24.57)
Research Supply Index2.71 (2.92)
Research Growth Index4.53 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (19.45)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies1 (7.14%)4.05%
Observational0 (0.00%)0.25%
Other13 (92.86%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]